Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT00002912
- Locations
- ๐บ๐ธ
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
๐บ๐ธChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธSimmons Cancer Center - Dallas, Dallas, Texas, United States
Combination Chemotherapy in Treating Children With Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT00002590
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธChildren's Hospital of Columbus, Columbus, Ohio, United States
๐บ๐ธChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Robert H. Lurie Cancer Center
- Registration Number
- NCT00004903
- Locations
- ๐บ๐ธ
University of Chicago Cancer Research Center, Chicago, Illinois, United States
๐บ๐ธRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Drexel University College of Medicine
- Registration Number
- NCT00003619
- Locations
- ๐บ๐ธ
Medical College of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธMedical College of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 36
- Registration Number
- NCT00003783
- Locations
- ๐บ๐ธ
West Virginia University Medical School, Charleston Division, Charleston, West Virginia, United States
๐บ๐ธSimmons Cancer Center - Dallas, Dallas, Texas, United States
๐บ๐ธArizona Cancer Center, Tucson, Arizona, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
- Conditions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002466
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
- Conditions
- Interventions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 29
- Registration Number
- NCT00003621
- Locations
- ๐บ๐ธ
CentraCare Clinic, Saint Cloud, Minnesota, United States
๐บ๐ธAltru Health Systems, Grand Forks, North Dakota, United States
๐บ๐ธCCOP - Ochsner, New Orleans, Louisiana, United States
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00002800
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
- Conditions
- Interventions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 51
- Registration Number
- NCT00002768
- Locations
- ๐บ๐ธ
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
๐บ๐ธMarlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
๐บ๐ธSt. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-04-20
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT00009815
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.